TORONTO, May 17, 2018 /CNW/ - GeneNews Ltd ("Genenews" or the
"Company") (TSX:GEN) today announced that it is partnering with AIM Laboratories ("AIM"), a privately held diagnostic laboratory
in St Louis, Missouri to offer its tests to AIM's client base. GeneNews will reciprocate by
offering AIM's tests to the Innovative Diagnostic Laboratory client base.
GeneNews, through Innovative Diagnostic Laboratory ("IDL"), its wholly-owned subsidiary in Richmond,
Virginia, operates a full service reference lab focused on early cancer risk stratification and diagnosis and has a strong
U.S. presence on the East and West coasts. AIM Laboratories operates a full service reference lab focused on routine blood
testing and specializing in therapeutic drug monitoring for prescribed and illicit drugs and services about 20 States with
particular strength in the Midwest.
"Combining forces and capitalizing on each company's geographic strengths will help both parties expand rapidly throughout the
U.S. Market," commented James R. Howard-Tripp, GeneNews' Chairman and CEO. "In addition, this
collaboration will give both companies the opportunity to expand their test menus in order to provide additional benefits to new
and existing practices and healthcare systems."
"IDL and AIM already work together in servicing some of IDL's clients in the Midwest," said Sonny
Naqvi, AIM's CEO. "This new agreement will allow us to expand operations together, particularly in the fast growing areas
of high-risk populations and telemedicine."
The collaboration will begin immediately.
About GeneNews
GeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized
medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. Our mission is
to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with
personalized clinical intelligence and actionable information to improve health out-comes through the early diagnosis of disease.
Our Richmond, Virginia-based Innovative Diagnostic Laboratory clinical reference lab specializes
in traditional and advanced clinical evidence-based blood testing that helps find, understand, and address cancer risk in patient
populations. Currently, IDL offers risk assessment blood tests for four prevalent cancer types - colon, lung, prostate and
breast. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on
GeneNews and IDL can be found at www.GeneNews.com and www.myinnovativelab.com, respectively.
About AIM Laboratories
AIM Laboratories is a premiere, community-based clinical laboratory strategically located in the center of the U.S., in
St. Louis Missouri. AIM Laboratories was established by a unique group of dedicated scientists
and business executives to provide the healthcare community with the highest level of localized science, service and support.
While our advanced facility and scientific staff are capable of running 1000 tests an hour, each of our clients receive superior,
prompt and individualized service.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions,
which reflect the Company's current expectations regarding future events, including the restructuring of its business. The
forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from
those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional
information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required
by law.
View original content:http://www.prnewswire.com/news-releases/genenews-announces-collaboration-with-aim-laboratories-to-expand-test-utilization-300650050.html
SOURCE GeneNews Limited
View original content: http://www.newswire.ca/en/releases/archive/May2018/17/c4350.html